New drug shrinks brain tumours in melanoma patients

May 21, 2012, University of Sydney

(Medical Xpress) -- Australian researchers have reported promising results with a new drug that shrinks brain tumours in melanoma patients. Their findings are published in The Lancet medical journal today.

Medical researchers at the University of Sydney, Melanoma Institute Australia, Sydney's Westmead Hospital and Westmead Millennium Institute, say a new drug they have been testing to treat deadly melanoma in the body also shows, for the first time, an ability to shrink secondary tumors (metastases) in the brains of with advanced forms of the disease.

They say the new drug may add months to the lives of patients whose melanoma has spread to the brain. Most patients with die within four months. The trial's results, however, showed in nine of the 10 patients shrank within the first six weeks. All 10 patients survived beyond five months, two patients survived beyond 12 months. One patient was alive at 19 months.

The drug called Dabrafenib works by targeting a found in melanoma cancer, called the BRAF mutation, which is present in 50 percent of human melanomas. The drug works by binding to the activated mutant form of the BRAF protein in the melanoma cell, causing the cell to stop proliferating. In many cases it shrinks and disappears.

The lead author of the study, Dr. Georgina Long, from the University of Sydney, Melanoma Institute Australia and Westmead Hospital said, "This is the first evidence that we have a systemic drug therapy that helps prolong survival in patients with multiple melanoma brain metastases. The findings are among the most important in the history of drug treatment for melanoma.

"Currently there is no effective systemic treatment for melanoma brain metastases, and patients whose cancer has spread to the brain are frequently excluded from promising clinical trials. Until now, there has not been a single drug that has shrunk brain metastases in more than 10 out of 100 patients with . This drug had a 90 percent success rate in reducing the size of brain metastases.

"Brain metastases in melanoma are a major unsolved problem. Up to this point, melanoma has been notoriously resistant to drug therapy in general, and responses in highly lethal brain are particularly uncommon. Providing these early data are supported in larger cohorts of patients and durable responses are confirmed, this activity in the brain may assist in addressing a large unmet need in patients with metastatic worldwide," Dr. Long said.

Explore further: Dabrafenib shrinks melanoma brain metastases in phase I clinical trial

Related Stories

Dabrafenib shrinks melanoma brain metastases in phase I clinical trial

May 17, 2012
An experimental drug targeting a common mutation in melanoma successfully shrank tumors that spread to the brain in nine out of 10 patients in part of an international phase I clinical trial report in the May 18 issue of ...

New drug, Vemurafenib, doubles survival of metastatic melanoma patients

March 1, 2012
A report published this week in the New England Journal of Medicine shows that the 50 percent of metastatic melanoma patients with a specific genetic mutation benefit from the drug Vemurafenib – increasing median survival ...

Ipilimumab active in advanced melanoma with brain mets

March 27, 2012
(HealthDay) -- For some patients with advanced melanoma and brain metastases, ipilimumab is active, according to the results of a phase 2 study published online March 27 in The Lancet Oncology.

P Rex-1 protein key to melanoma metastasis

November 22, 2011
Researchers from UNC Lineberger Comprehensive Cancer Center are part of a team that has identified a protein, called P-Rex1, that is key to the movement of cells called melanoblasts. When these cells experience uncontrolled ...

Recommended for you

Research could help fine-tune cancer treatment

May 25, 2018
Cancer therapies that cut off blood supply to a tumour could be more effective in combination with existing chemotherapeutic drugs—according to new research from the University of East Anglia.

Increasing physical activity linked to better immunity in breast cancer patients, study finds

May 25, 2018
A new study from the University of Toronto's Faculty of Kinesiology & Physical Education has found that moderate to vigorous physical activity may help regulate the levels of C-reactive protein – an important biomarker ...

Study finds gut microbiome can control antitumor immune function in liver

May 24, 2018
Scientists have found a connection between bacteria in the gut and antitumor immune responses in the liver. Their study, published May 25 in Science, was led by researchers in the Center for Cancer Research (CCR) at the National ...

Low-fat diet tied to better breast cancer survival

May 24, 2018
(HealthDay)—Breast cancer patients who adopted a low-fat diet were more likely to survive for at least a decade after diagnosis, compared to patients who ate fattier fare, new research shows.

A cascade of immune processes offers insights to triple-negative breast cancer

May 24, 2018
Cancer is crafty. To survive and thrive, tumors find a way of thwarting our body's natural systems.

By forming clots in tumors, immune cell aids lung cancer's spread

May 24, 2018
University of North Carolina Lineberger Comprehensive Cancer Center researchers have found that by helping to form clots within tumors, immune cells that flock to a particular type of lung cancer are actually building a foundation ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.